Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1CNS 1

Conditions

Obesity 1Craniopharyngioma 1

Interventions

naloxegol 7alvimopan 6Radiotherapy 5angiotensin I (1-7) 4Cisplatin 4tegaserod 3Injections 3RRx-001 2Fibroblast Growth Factor 7 2tempol 1prucalopride 1oxycodone naloxone combination 1naldemedine 1methylnaltrexone 1linaclotide 1licogliflozin 1hydrated silica gel-based toothpaste 1golotimod 1brilacidin 1apraglutide 1amlexanox 1aluminum hydroxide, magnesium hydroxide, drug combination 1Xylitol 1Water 1Therapeutics 1Testosterone Propionate 1Robotic Surgical Procedures 1Radiotherapy, Intensity-Modulated 1Phenylephrine 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × CKD732 × Other × Clear all
NCT02063295 2016-07-18

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Zafgen, Inc.

Phase 2 Completed
14 enrolled
CNSOther

Craniopharyngioma, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡